

Prakash Deedwania

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11879782/publications.pdf>

Version: 2024-02-01

74
papers

9,526
citations

94433

37
h-index

79698

73
g-index

76
all docs

76
docs citations

76
times ranked

10879
citing authors

#	ARTICLE	IF	CITATIONS
19	A comparative analysis of the results from 4 trials of β -blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. <i>Journal of Cardiac Failure</i> , 2003, 9, 354-363.	1.7	164
20	Regional variations in cardiovascular risk factors in India: India heart watch. <i>World Journal of Cardiology</i> , 2012, 4, 112.	1.5	164
21	Resting Heart Rate: Risk Indicator and Emerging Risk Factor in Cardiovascular Disease. <i>American Journal of Medicine</i> , 2015, 128, 219-228.	1.5	161
22	Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy. <i>Circulation</i> , 2012, 125, 1979-1987.	1.6	149
23	Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial. <i>American Heart Journal</i> , 2001, 142, 502-511.	2.7	115
24	Prevalence of hypertension among Indian adults: Results from the great India blood pressure survey. <i>Indian Heart Journal</i> , 2019, 71, 309-313.	0.5	110
25	What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker?. <i>Journal of the American College of Cardiology</i> , 2005, 45, 252-259.	2.8	96
26	Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2018, 3, 288.	6.1	93
27	Relation of Baseline Systolic Blood Pressure and Long-Term Outcomes in Ambulatory Patients With Chronic Mild to Moderate Heart Failure. <i>American Journal of Cardiology</i> , 2011, 107, 1208-1214.	1.6	92
28	Tolerability of β -Blocker Initiation and Titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). <i>Circulation</i> , 2002, 105, 1182-1188.	1.6	87
29	Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study. <i>European Journal of Heart Failure</i> , 2011, 13, 200-206.	7.1	87
30	Sotalol. <i>Drugs</i> , 1987, 34, 311-349.	10.9	86
31	Ambulatory ECG-Based T-wave Alternans Predicts Sudden Cardiac Death in High-Risk Post-MI Patients with Left Ventricular Dysfunction in the EPHEBUS Study. <i>Journal of Cardiovascular Electrophysiology</i> , 2008, 19, 1037-1042.	1.7	83
32	Hypertension, Dyslipidemia, and Insulin Resistance in Patients With Diabetes Mellitus or the Cardiometabolic Syndrome: Benefits of Vasodilating β -Blockers. <i>Journal of Clinical Hypertension</i> , 2011, 13, 52-59.	2.0	66
33	Frequent Atrial Premature Complexes and Their Association With Risk of Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2015, 116, 1852-1857.	1.6	56
34	Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome. <i>Current Hypertension Reports</i> , 2016, 18, 76.	3.5	51
35	Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy. <i>JAMA Cardiology</i> , 2021, 6, 139.	6.1	50
36	Impact of Baseline Systolic Blood Pressure on Long-Term Outcomes in Patients With Advanced Chronic Systolic Heart Failure (Insights from the BEST Trial). <i>American Journal of Cardiology</i> , 2010, 106, 221-227.	1.6	44

#	ARTICLE	IF	CITATIONS
37	Renin-Angiotensin-Aldosterone Blockade for Cardiovascular Disease Prevention. <i>Cardiology Clinics</i> , 2011, 29, 137-156.	2.2	40
38	Cholesterol lipoproteins and prevalence of dyslipidemias in urban Asian Indians: A cross sectional study. <i>Indian Heart Journal</i> , 2014, 66, 280-288.	0.5	40
39	Lipid-Lowering Therapy with Statins for the Primary and Secondary Prevention of Cardiovascular Disease. <i>Cardiology Clinics</i> , 2011, 29, 87-103.	2.2	37
40	Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure. <i>American Journal of Medicine</i> , 2015, 128, 715-721.	1.5	36
41	Calcium Channel Blockers and Outcomes in Older Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 945-952.	3.9	32
42	Temporal Trends for Secondary Prevention Measures Among Patients Hospitalized with Coronary Artery Disease. <i>American Journal of Medicine</i> , 2015, 128, 426.e1-426.e9.	1.5	31
43	Usefulness of Abnormal Heart Rate Turbulence to Predict Cardiovascular Mortality in High-Risk Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction (from the EPHEBUS) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10</i>	1.6	24
44	Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462</i>	1.6	24
45	The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 51-57.	5.1	21
46	Primary and Secondary Prevention Strategy for Cardiovascular Disease in Diabetes Mellitus. <i>Cardiology Clinics</i> , 2011, 29, 47-70.	2.2	19
47	Low High-Density Lipoprotein Cholesterol and Increased Cardiovascular Disease Risk: An Analysis of Statin Clinical Trials. <i>American Journal of Cardiology</i> , 2009, 104, 3E-9E.	1.6	18
48	Diabetes and vascular disease. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 127-138.	1.5	17
49	Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelinesâ€“Coronary Artery Disease (GWTG-CAD) program. <i>American Heart Journal</i> , 2017, 187, 78-87.	2.7	17
50	Similar clinical benefits from belowâ€“target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. <i>European Journal of Heart Failure</i> , 2018, 20, 359-369.	7.1	17
51	Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone. <i>International Journal of Cardiology</i> , 2017, 227, 462-466.	1.7	16
52	An Overview of Glycemic Control in the Coronary Care Unit with Recommendations for Clinical Management. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 1342-1351.	2.2	15
53	Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial. <i>Journal of the American Society of Hypertension</i> , 2009, 3, 210-220.	2.3	15
54	Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. <i>American Journal of Medicine</i> , 2021, 134, e252-e263.	1.5	14

#	ARTICLE	IF	CITATIONS
55	How Should Subgroup Analyses Affect Clinical Practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 264-275.	1.0	13
56	An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation. <i>Core Evidence</i> , 2012, 7, 49.	4.7	12
57	A Propensity-Matched Study of the Association of Diabetes Mellitus With Incident Heart Failure and Mortality Among Community-Dwelling Older Adults. <i>American Journal of Cardiology</i> , 2011, 108, 1747-1753.	1.6	11
58	Characteristics and Outcomes of Patients With Advanced Chronic Systolic Heart Failure Receiving Care at the Veterans Affairs Versus Other Hospitals. <i>Circulation: Heart Failure</i> , 2015, 8, 17-24.	3.9	11
59	The safety and tolerability of beta blockers in heart failure with reduced ejection fraction: is the current underutilization of this evidence-based therapy justified?. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1855-1863.	2.4	11
60	Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials. <i>Journal of Clinical Lipidology</i> , 2019, 13, 586-593.e5.	1.5	11
61	The endocannabinoid system and cardiometabolic risk: Effects of CB1 receptor blockade on lipid metabolism. <i>International Journal of Cardiology</i> , 2009, 131, 305-312.	1.7	8
62	Evolving Treatment Options for Prevention of Cardiovascular Events in High-Risk Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2007, 9, 883-888.	2.0	7
63	Management of coronary artery disease in patients with type 2 diabetes mellitus. <i>Current Cardiology Reports</i> , 2007, 9, 264-271.	2.9	7
64	Impact of the 2017 ACC/AHA guidelines on the prevalence of hypertension among Indian adults: Results from a cross-sectional survey. <i>International Journal of Cardiology: Hypertension</i> , 2020, 7, 100055.	2.2	7
65	Reducing morbidity and mortality in high risk patients with statins. <i>Vascular Health and Risk Management</i> , 2009, 5, 495.	2.3	6
66	A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance and High Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2013, 112, 231-237.	1.6	5
67	Updated risk factors should be used to predict development of diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 859-863.	2.3	5
68	Anticoagulation in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 786-788.	2.8	4
69	Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation. <i>International Journal of Angiology</i> , 2015, 24, 105-112.	0.6	3
70	An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. <i>Core Evidence</i> , 2015, 10, 63.	4.7	2
71	Is Increased Use of Mechanical Circulatory Support Devices Justified?. <i>JAMA Internal Medicine</i> , 2015, 175, 1982.	5.1	2
72	Racial differences in mortality in patients with advanced systolic heart failure: Potential role of right ventricular ejection fraction. <i>International Journal of Cardiology</i> , 2014, 177, 255-260.	1.7	1

#	ARTICLE	IF	CITATIONS
73	Mechanical Circulatory Support and Rationale for Future Research”Reply. JAMA Internal Medicine, 2016, 176, 715.	5.1	0
74	An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs. Reviews in Cardiovascular Medicine, 2012, 13, e89-104.	1.4	0